Inducing cell death by hyperactivation of motility networks

Patent metadata

Field	Value
Publication number	US-11878045-B2
Application number	US-202017106000-A
Country	US
Kind code	B2
Filing date	Nov 27, 2020
Priority date	Feb 29, 2016
Publication date	Jan 23, 2024
Grant date	Jan 23, 2024

Abstract

The present invention provides a method of inducing cell death by hyperactivation of motility networks.

First claim

We claim:

1. A method of treating neoplasia in a subject comprising:
administering an agent or stressor that selectively kills a neoplastic cell of the subject by further activating or hyper-activating the cell,
wherein the neoplastic cell bears a mutated oncogene or a mutated tumor suppressor gene,
wherein the gene comprises Ras, PI3K, PTEN, or combinations thereof, thereby treating the neoplasia in the subject.

2. The method of claim 1 , wherein the subject has been diagnosed with a neoplasia.

3. The method of claim 1 , wherein the subject is a human or domesticated animal.

4. The method of claim 1 , wherein the neoplastic cell comprises a metastatic cell or a pre-metastatic cell.

5. The method of claim 1 , wherein further activating or hyper-activating the cell induces spreading and flattening of the cell.

6. The method of claim 1 , wherein the cell undergoes fragmentation.

7. The method of claim 6 , wherein the fragmentation comprises catastrophic fragmentation.

8. The method of claim 1 , wherein the agent or stressor comprises an environmental perturbation.

9. The method of claim 8 , wherein the environmental perturbation comprises a mechanical force, a temperature change, an electrical stimulus, a sound wave, osmotic shock, or other environmental change.

10. The method of claim 1 , wherein the administered agent comprises a statin, a phenothiazine, an antibiotic, an analgesic or combinations thereof.

11. The method of claim 1 , wherein the administered agent comprises a statin.

12. The method of claim 11 , wherein the statin comprises pitavastatin, fluvastatin, atorvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin.

13. The method of claim 1 , wherein the statin comprises pitavastatin.

14. The method of claim 1 , wherein the administered agent comprises a phenothiazine.

15. The method of claim 1 , wherein the administered agent comprises an antibiotic.

16. The method of claim 1 , wherein the administered agent comprises an analgesic.

17. The method of claim 1 , wherein the subject is a human.

Assignees

• Univ Johns Hopkins

Inventors

• Devreotes Peter
• Cai Huaqing
• Edwards Marc
• Liu Jun
• Lampert Thomas
• Long Yu

Classifications

• A61K38/12 Primary

  Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K31/22

  of acyclic acids, e.g. pravastatin · CPC title